Craig A. Collard, the Chief Executive Officer of Heron Therapeutics, Inc., has made significant stock transactions, acquiring nearly 14,000 shares of the company. This move, reported in a recent SEC filing, underscores his confidence in Heron Therapeutics as it navigates the complexities of the pharmaceutical industry.
According to the filing, dated October 21, 2026, Collard acquired 13,797 shares through a transaction dated October 19, 2026. Additionally, he reported the acquisition of 3,360 shares at a price of $0.36 each. Following these transactions, Collard owns a total of 866,929 shares of Heron Therapeutics.
Background
Heron Therapeutics, Inc. is a pharmaceutical company incorporated in Delaware, focused on developing innovative products for patients with unmet medical needs. The company operates under the SIC code for Pharmaceutical Preparations. Recent filings indicate that Collard has been actively managing his ownership stake, with multiple transactions reported over the past several months.
What the Filing Says
The SEC filing details Collard's transactions, stating, "Collard acquired 13,797 shares of common stock and 3,360 shares at a price of $0.36 each." This acquisition reflects a direct ownership nature, emphasizing his commitment to the company's future.
Impact
This move may affect various stakeholders, including investors and employees of Heron Therapeutics. Collard's significant share acquisition could be interpreted as a strong vote of confidence in the company's direction, potentially influencing investor sentiment and employee morale.
What's Next
The filing does not say what happens next.